dactinomycin

(redirected from actinomycin-D)
Also found in: Dictionary.

dactinomycin

 [dak″tĭ-no-mi´sin]
an antitumor antibiotic of the actinomycin complex (actinomycin D), produced by Streptomyces parvulus. Used to treat rhabdomyosarcoma and Wilms' tumor in children, as well as Ewing's sarcoma, Kaposi's sarcoma, osteogenic sarcoma, soft tissue sarcomas, testicular carcinoma, and choriocarcinoma.

dac·ti·no·my·cin

(dak'ti-nō-mī'sin),
An antineoplastic antibiotic produced by several species of Streptomyces (for example, S. parvulus).
See also: actinomycins.
Synonym(s): actinomycin D

dactinomycin

/dac·ti·no·my·cin/ (dak″tĭ-no-mi´sin) actinomycin D, an antibiotic derived from several species of Streptomyces; used as an antineoplastic.

dactinomycin

(dăk′tə-nō-mī′sĭn)
n.
An antibiotic of the actinomycin group, C62H86N12O16, isolated from bacteria and used as an antineoplastic agent in the treatment of certain cancers. Also called actinomycin D.

dactinomycin

[dak′tinōmī′sin]
an antibiotic used as an antineoplastic agent.
indications It is prescribed in the treatment of a variety of malignant neoplastic diseases, including testicular cancer, melanoma, Wilms' tumor, and rhabdomyosarcoma.
contraindications Herpes zoster infection, chickenpox, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the more serious adverse reactions are bone marrow depression, severe GI disturbances, proctitis, alopecia, and ulcers of the mouth.

Actinomycin D

A relatively toxic antibiotic produced by Streptomyces spp, which is used as a chemotherapeutic.
Mechanism Inhibits DNA transcription by RNA polymerase.
Indications Rhabdomyosarcoma, Wilms’ tumour, gestational trophoblastic tumour 
Adverse effects Anorexia, nausea, vomiting, myelosuppression with pancytopenia, diarrhoea

dactinomycin

Oncology An antitumor antibiotic member of a class of drugs first isolated from Streptomyces, and used to treat Wilms' tumor, Ewing sarcoma, embryonal rhabdomyosarcoma, choriocarcinoma, seminoma, KS, lymphoma

dac·ti·no·my·cin

(dak'ti-nō-mī'sin)
An antineoplastic antibiotic produced by several species of Streptomyces (e.g., S. parvulus).

dactinomycin

A cytotoxic drug used to treat cancers mainly of children. Dactinomycin is an antibiotic derived from Streptomyces pavullus which causes breaks in DNA. This side effect renders it unsuitable as an antibacterial drug, but makes it useful as an anti-cancer drug. A brand name is Cosmegen Lyovac. There are other actinomycins in the group produced by Streptomyces chrysomallas .

dac·ti·no·my·cin

(dak'ti-nō-mī'sin)
An antineoplastic antibiotic produced by several species of Streptomyces (e.g., S. parvulus).

dactinomycin

an antibiotic of the actinomycin complex (actinomycin D), produced by several species of Streptomyces; used as an antineoplastic agent.
References in periodicals archive ?
Preliminary results of the study indicate that actinomycin-D is not effective in preventing restenosis and patients treated with actinomycin-D eluting stents have an unacceptably high target lesion revascularization rate.
This collaboration, coupled with the rapid progress we have made on our internal PHARMA-LINK(TM) Drug Coated Stent Program utilizing Actinomycin-D, demonstrates our commitment to bring this promising therapy to patients as quickly as possible.
As we rapidly advance in the clinical evaluation phase in both the paclitaxel-coated stent provided through our agreement with Cook, and our internal PHARMA-LINK(TM) Drug Eluting Stent Program utilizing Actinomycin-D, we are well on our way toward providing our customers with the broadest and deepest drug-coated stent product line in the industry.